Cargando…

Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis

T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Schrom, Kory P, Kobs, Alison, Nedorost, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249757/
https://www.ncbi.nlm.nih.gov/pubmed/32467806
http://dx.doi.org/10.7759/cureus.7831
_version_ 1783538649454870528
author Schrom, Kory P
Kobs, Alison
Nedorost, Susan
author_facet Schrom, Kory P
Kobs, Alison
Nedorost, Susan
author_sort Schrom, Kory P
collection PubMed
description T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient, we posited that dupilumab would benefit autoeczematization secondary to chronic stasis dermatitis given its efficacy in atopic dermatitis, a Th2-mediated immune process. We report a case of clinical psoriasiform dermatitis, suggesting a shift toward a Th1-mediated immune process developing during dupilumab treatment for autoeczematization secondary to chronic stasis dermatitis.
format Online
Article
Text
id pubmed-7249757
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-72497572020-05-27 Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis Schrom, Kory P Kobs, Alison Nedorost, Susan Cureus Dermatology T helper 2 (Th2) and T helper 1 (Th1) mediated immune processes lie on a spectrum. Autoeczematization secondary to chronic stasis dermatitis may fall on the Th2 side of the spectrum due to skin stretch and chronic barrier dysfunction, supporting a primary Th2 response to self-antigen. In our patient, we posited that dupilumab would benefit autoeczematization secondary to chronic stasis dermatitis given its efficacy in atopic dermatitis, a Th2-mediated immune process. We report a case of clinical psoriasiform dermatitis, suggesting a shift toward a Th1-mediated immune process developing during dupilumab treatment for autoeczematization secondary to chronic stasis dermatitis. Cureus 2020-04-25 /pmc/articles/PMC7249757/ /pubmed/32467806 http://dx.doi.org/10.7759/cureus.7831 Text en Copyright © 2020, Schrom et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Schrom, Kory P
Kobs, Alison
Nedorost, Susan
Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title_full Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title_fullStr Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title_full_unstemmed Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title_short Clinical Psoriasiform Dermatitis Following Dupilumab Use for Autoeczematization Secondary to Chronic Stasis Dermatitis
title_sort clinical psoriasiform dermatitis following dupilumab use for autoeczematization secondary to chronic stasis dermatitis
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249757/
https://www.ncbi.nlm.nih.gov/pubmed/32467806
http://dx.doi.org/10.7759/cureus.7831
work_keys_str_mv AT schromkoryp clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis
AT kobsalison clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis
AT nedorostsusan clinicalpsoriasiformdermatitisfollowingdupilumabuseforautoeczematizationsecondarytochronicstasisdermatitis